Ovarian tumor immune landscapes offer clues to better therapy

The immune system is a major determinant of how patients respond to standard treatments for ovarian cancer, the leading cause of death from gynecological malignancies. But little was known about how the immune landscape of tumors changes when patients relapse—as they frequently do—or how those changes influence responses to subsequent therapy, which tend to be dismal.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup